Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1998-02-17
2000-12-19
Celsa, Bennett
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 19, 530330, 530331, A61K 3800
Patent
active
061627909
ABSTRACT:
The present invention relates to novel classes of compounds which are inhibitors of interleukin-1 .beta. converting enzyme. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting ICE activity and consequently, may be advantageously used as agents against interleukin-1 and apoptosis-mediated diseases, including inflammatory diseases, autoimmune diseases, proliferative, infectious, and degenerative diseases. This invention also relates to methods for inhibiting ICE activity and methods for treating interleukin-1 mediated diseases using the compounds and compositions of this invention.
REFERENCES:
patent: 4276298 (1981-06-01), Jones et al.
patent: 4369183 (1983-01-01), Jones et al.
patent: 4499295 (1985-02-01), Mueller et al.
patent: 4551279 (1985-11-01), Mueller et al.
patent: 4584397 (1986-04-01), Mueller et al.
patent: 4968607 (1990-11-01), Dower et al.
patent: 5008245 (1991-04-01), Digenis et al.
patent: 5055451 (1991-10-01), Krantz et al.
patent: 5081228 (1992-01-01), Dower et al.
patent: 5158936 (1992-10-01), Krantz et al.
patent: 5180812 (1993-01-01), Dower et al.
patent: 5374623 (1994-12-01), Zimmerman et al.
patent: 5411985 (1995-05-01), Bills et al.
patent: 5416013 (1995-05-01), Black et al.
patent: 5430128 (1995-07-01), Chapman et al.
patent: 5434248 (1995-07-01), Chapman et al.
patent: 5462939 (1995-10-01), Dolle et al.
patent: 5486623 (1996-01-01), Zimmerman et al.
patent: 5498616 (1996-03-01), Mallamo et al.
patent: 5498695 (1996-03-01), Daumy et al.
patent: 5527882 (1996-06-01), Mitchell et al.
patent: 5552400 (1996-09-01), Dolle et al.
patent: 5565430 (1996-10-01), Dolle et al.
patent: 5843904 (1998-12-01), Bemis et al.
M. Ator, "Peptide and Non-peptide Inhibitors of Interleukin-1.beta. Converting Enzyme", Cambridge Healthtech Institute (Inflammatory Cytokine Antagonists Targets, Strategies and Indication), (1994).
M.A. Ator and R.E. Dolle, "Interleukin-1.beta. Converting Enzyme: Biology and the Chemistry of Inhibitors", Curr. Pharm. Design, 1, pp. 191-210 (1995).
M. Barinaga, "Death Gives Birth to the Nervous System. But How?", Science, 259, pp. 762-763 (1993).
P. Bender & J. Lee, "Pharmacological Modulation of Interleukin-1", Annu. Rep. Med. Chem., 25, pp. 185-193 (1989).
R. Black et al., "Activation of Interleukin-1.beta. by a Co-induced Protease", FEBS Lett., 247, pp. 386-390 (1989).
J. Breitner et al., "Inverse Association of Anti-inflammatory Treatments and Alzheimer's Disease: Initial Results of a Co-twin Control Study", Neurology, 44, pp. 227-232 (1994).
F. Casano et al., "The Structure and Complete Nucleotide Sequence of the Murine Gene Encoding Interleukin-1.beta. Converting Enzyme (ICE)", Genomics, 20, pp. 474-481 (1994).
D. Cerretti et al., "Molecular Cloning of the Interleukin-1.beta. Converting Enzyme", Science, 256, pp. 97-100 (1992).
K. Chapman, "Synthesis of a Potent, Reversible Inhibitor of Interleukin-1.beta. Converting Enzyme", Bioorg. Med. Chem. Lett., 2, pp. 613-618 (1992).
C. Dinarello, "Role of Interleukin-1 in Infectious Diseases", Immunol. Rev., 127, pp. 119-146 (1992).
C. Dinarello et al., "Anticytokine Strategies in the Treatment of the Systemic Inflammatory Response Syndrome", J. Am. Med. Assoc., 269, pp. 1829-1835 (1993).
R. Dolle et al., "Aspartyl .alpha.-((1-Phenyl-3-(trifluoromethyl)-pyrazole-5-yl)oxy)methyl Ketones as Interleukin-1.beta. Converting Enzyme Inhibitors. Significance of the P.sub.1 and P.sub.3 Amido Nitrogens for Enzyme-Peptide Inhibitor Binding", J. Med. Chem., 37, pp. 3863-3865 (1994).
R. Dolle et al., "Aspartyl .alpha.-((Diphenylphosphinyl)oxy)methyl Ketones as Novel Inhibitors of Interleukin-1.beta. Converting Enzyme. Utility of the Diphenylphosphinic Acid Leaving Group for the Inhibition of Cysteine Proteases", J. Med. Chem., 38, pp. 220-222 (1995).
R. Dolle et al., "P.sub.1 Aspartate-Based Peptide .alpha.-((2,6-Dichlorobenzoyl)oxy)methyl Ketones as Potent Time-Dependent Inhibitors of Interleukin-1.beta.-Converting Enzyme", J. Med. Chem., 37, pp. 563-564 (1994).
P. Edwards et al., "Design, Synthesis, and Kinetic Evaluation of a Unique Class of Elastase Inhibitors, the Peptidyl .alpha.-Ketobenzoxazoles, and the X-ray Crystal Structure of the Covalent Complex between Porcine Pancreatic Elastase and Ac-Ala-Pro-Val-2-Benzoxazole", J. Am. Chem. Soc., 114, pp. 1854-1863 (1992).
T. Fan et al., "Stimulation of Angiogenesis by Substance P and Interleukin-1 in the Rat and Its Inhibition by NK.sub.1 or Interleukin-1 Receptor Antagonists", Br. J. Pharmacol., 110, pp. 43-49 (1993).
I. Fauszt et al., "Inhibition of Interleukin-1.beta. Converting Enzyme by Peptide Derivatives", Proc. of the 13th Am. Peptide Symp., Jun. 20-25, 1993, Hodges, R.S. and Smith, J.A., Eds., Peptides, pp. 589-591 (1994).
D.S. Fletcher et al., "A Synthetic Inhibitor of Interleukin-1.beta. Converting Enzyme Prevents Endotoxin-Induced Interleukin-1.beta. Production In Vitro and In Vivo", J. Interfer. Cytokine Res., 15, pp. 243-248 (1995).
V. Gagliardini et al., "Prevention of Vertebrate Neuronal Death by the crmA Gene", Science, 263, pp. 826-828 (1994).
T. Geiger et al., "Neutralization of Interleukin-1.beta. Activity in vivo with a Monoclonal Antibody Alleviates Collagen-induced Arthritis in DBA/1 Mice and Prevents the Associated Acute-phase Response", Clin. Exp. Rheumatol., 11, pp. 515-522 (1993).
T. Graybill et al., "The Preparation and Evaluation of Peptidic Aspartyl Hemiacetals as Reversible Inhibitors of ICE", Am. Chem. Soc. Abs. (206th Natl. Mtg.), MEDI 235 (1993).
T. Graybill et al., "Preparation and evaluation of peptidic aspartyl hemiacetals as reversible inhibitors of interleukin-1.beta. converting enzyme (ICE)", Int. J. Peptide Protein Res., 44, pp. 173-182 (1994).
T. Graybill et al., "Synthesis and Evaluation of Diacylhydrazines as Inhibitors of the Interleukin-1.beta. Converting Enzyme (ICE)", Bioorg. Med. Chem. Lett., 5, pp. 1197-1202 (1995).
W. Griffin et al., "Brain Interleukin 1 and S-100 Immunoreactivity are Elevated in Down Syndrome and Alzheimer Disease", Proc. Natl. Acad. Sci. USA, 86, pp. 7611-7615 (1989).
C. Hammerberg et al., "Interleukin-1 Receptor Antagonist in Normal and Psoriatic Epidermis", J. Clin. Invest., 90, pp. 571-583 (1992).
S. Hanessian et al., "Design and Synthesis of a Prototype Model Antagonist of Tachykinin NK-2 Receptor", Biorg. Med. Chem. Lett., 3, pp. 2689-2692 (1993).
E. Harris, "Rheumatoid Arthritis: Pathophysiology and Implications for Therapy", N. Eng. J. Med., 322, pp. 1277-1289 (1990).
A. Howard et al., "High-Level Production and Characterization of Functional Human Interleukin-1.beta. Converting Enzyme in Baculovirus and E. coli Expression Systems", J. Cell. Biochem. Suppl., 17B, p. 146 (1993).
A. Howard et al., "Human Interleukin-1.beta. Converting Enzyme: A Mutational Analysis of Proenzyme Activation", J. Cell. Biochem. Suppl., 17B, p. 113 (1993).
A. Howard et al., "IL-1-Converting Enzyme Requires Aspartic Acid Residues for Processing of the IL-1.beta. Precursor at Two Distinct Sites and Does Not Cleave 31-kDa IL-1.alpha.", J. Immunol., 147, pp. 2964-2969 (1991).
I. Kamphuis et al., "Thiol Proteases: Comparative Studies Based on the High-resolution Structures of Papain and Actinidin, and on Amino Acid Sequence Information for Cathepsins B and H, and Stem Bromelain", J. Mol. Biol., 182, pp. 317-329 (1985).
M. Kostura et al., "Identification of a Monocyte Specific Pre-Interleukin 1.beta. Convertase Activity", Proc. Natl. Acad. Sci. USA, 86, pp. 5227-5231 (1989).
K. Kuida et al., "Altered Cytokine Export and Apoptosis in Mice Deficient in Interleukin-1.beta. Converting Enzyme", Science, 267, pp. 2000-2003 (1995).
P. Li et al., "Mice Deficient in IL-1.beta.-Converting Enzyme are Defective in Production of Mature IL-1.beta. and Resistant to Endotoxic Shock", Cell, 80, pp. 401-411 (1995).
C. Lipinski, "Bioisosterism in Drug Design", Annu. Rep. Med. Chem., 21, pp. 283-291 (1986).
G. Lonnemann et al., "Differences in the Synthesis and Kinetics of Release of Interleukin 1.
Bemis Guy W.
Duffy John P.
Fridman Wolf Herman
Golec Julian M. C.
Livingston David J.
Celsa Bennett
Dixon Lisa A.
Haley, Jr. James F.
Vertex Pharmaceuticals Incorporated
LandOfFree
Inhibitors of interleukin-1.beta. converting enzyme does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibitors of interleukin-1.beta. converting enzyme, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of interleukin-1.beta. converting enzyme will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-271356